Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Replimune Group, Inc. operates as a clinical-stage bio-technology company. The Company discovers and develops oncolytic immunotherapy for the treatment of patients with cancer diseases. Replimune Group serves customers in the United States.
Website: replimune.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.04 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 59.2% (LTM)

Entry Point: Share price is 0.0% higher than minimum and 83.7% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: REPL
Share price, USD:  (-7.5%)6.45
year average price 14.26  


year start price 17.25 2023-04-22

max close price 24.10 2023-06-13

min close price 6.45 2024-04-19

current price 6.45 2024-04-20
Common stocks: 57 857 132

Dividend Yield:  0.0%
Last revenue growth (y/y):  0.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 373
Net Debt ($m): -159
EV (Enterprise Value): 214
Price to Book: 0.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-11Zacks Investment Research

How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%

2024-03-08Zacks Investment Research

What Makes Replimune Group, Inc. (REPL) a New Buy Stock

2024-02-23Zacks Investment Research

Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?

2023-12-05InvestorPlace

Why Is Replimune (REPL) Stock Down 48% Today?

2023-08-14Seeking Alpha

Replimune: Q4 2023 Data Readouts Of RP1 Makes This A Must Watch

2023-07-09Seeking Alpha

Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment

2023-06-01GlobeNewsWire

Replimune to Present at the Jefferies Global Healthcare Conference

2023-05-25GlobeNewsWire

Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

2023-05-17Zacks Investment Research

Is a Surprise Coming for Replimune (REPL) This Earnings Season?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol REPL REPL REPL REPL REPL REPL
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-08 2023-11-07 2023-08-03 2023-05-18 2023-02-09 2022-11-03
acceptedDate 2024-02-08 08:09:58 2023-11-07 17:03:40 2023-08-03 08:11:14 2023-05-18 08:10:56 2023-02-09 08:17:33 2022-11-03 08:13:22
calendarYear 2024.000 2024.000 2024.000 2023.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 0 0 0
costOfRevenue 700 000 700 000 0 0 0 0
grossProfit -700 000 -700 000 0 0 0 0
grossProfitRatio 0 0 0 0 0 0
researchAndDevelopmentExpenses 43M 49M 40M 38M 30M 29M
generalAndAdministrativeExpenses 0 0 0 24M 0 13M
sellingAndMarketingExpenses 0 0 0 -9M 0 0
sellingGeneralAndAdministrativeExpenses 14M 15M 15M 15M 11M 13M
otherExpenses 1M -1M 1M -882 000 -607 000 -574 000
operatingExpenses 56M 63M 55M 52M 41M 41M
costAndExpenses 56M 63M 55M 52M 41M 41M
interestIncome 6M 6M 0 0 0 0
interestExpense 2M 1M 2M 2M 1M 550 000
depreciationAndAmortization 675 000 654 000 621 000 265 000 1M -1M
ebitda -54M -64M -53M -53M -40M -43M
ebitdaratio 0 0 0 0 0 0
operatingIncome -57M -64M -56M -53M -42M -42M
operatingIncomeRatio 0 0 0 0 0 0
totalOtherIncomeExpensesNet 7M 5M 8M 4M 2M -2M
incomeBeforeTax -51M -60M -49M -49M -40M -43M
incomeBeforeTaxRatio 0 0 0 0 0 0
incomeTaxExpense 473 000 -201 000 201 000 4M -3M -1M
netIncome -51M -60M -50M -53M -37M -42M
netIncomeRatio 0 0 0 0 0 0
eps -0.770 -0.900 -0.750 -0.920 -0.640 -0.770
epsdiluted -0.770 -0.900 -0.750 -0.920 -0.640 -0.770
weightedAverageShsOut 67M 67M 66M 58M 58M 55M
weightedAverageShsOutDil 67M 67M 66M 58M 58M 55M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol REPL REPL REPL REPL REPL REPL
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-08 2023-11-07 2023-08-03 2023-05-18 2023-02-09 2022-11-03
acceptedDate 2024-02-08 08:09:58 2023-11-07 17:03:40 2023-08-03 08:11:14 2023-05-18 08:10:56 2023-02-09 08:17:33 2022-11-03 08:13:22
calendarYear 2024.000 2024.000 2024.000 2023.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 98M 76M 106M 147M 207M 89M
shortTermInvestments 369M 421M 433M 437M 410M 283M
cashAndShortTermInvestments 466M 497M 539M 583M 616M 372M
netReceivables 4M 3M 3M 3M 2M 3M
inventory 0 0 0 0 0 0
otherCurrentAssets 9M 9M 8M 6M 6M 5M
totalCurrentAssets 479M 508M 550M 593M 624M 379M
propertyPlantEquipmentNet 52M 52M 52M 52M 53M 54M
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 2M 2M 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 0 0 2M 2M 2M 3M
totalNonCurrentAssets 54M 54M 54M 54M 55M 57M
otherAssets 0 0 0 0 0 0
totalAssets 533M 562M 604M 647M 679M 436M
accountPayables 4M 4M 5M 5M 4M 4M
shortTermDebt 4M 4M 4M 4M 4M 4M
taxPayables 0 0 0 0 0 0
deferredRevenue 27M 28M 21M 0 0 0
otherCurrentLiabilities 4M 4M 24M 25M 19M 16M
totalCurrentLiabilities 39M 40M 32M 34M 26M 24M
longTermDebt 72M 57M 57M 57M 57M 28M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 793 000 472 000 578 000 472 000 0 21M
totalNonCurrentLiabilities 73M 57M 58M 57M 57M 28M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 31M 32M 32M 32M 32M 32M
totalLiabilities 111M 97M 90M 91M 83M 52M
preferredStock 0 0 0 0 0 0
commonStock 61 000 59 000 57 000 57 000 57 000 50 000
retainedEarnings -646M -595M -535M -485M -436M -397M
accumulatedOtherComprehensiveIncomeLoss 5M 5M 4M 6M 4M 3M
othertotalStockholdersEquity 1 063M 1 055M 1 045M 1 035M 1 028M 778M
totalStockholdersEquity 422M 465M 514M 555M 595M 384M
totalEquity 422M 465M 514M 555M 595M 384M
totalLiabilitiesAndStockholdersEquity 533M 562M 604M 647M 679M 436M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 533M 562M 604M 647M 679M 436M
totalInvestments 369M 421M 433M 437M 410M 283M
totalDebt 76M 61M 61M 61M 60M 32M
netDebt -22M -15M -46M -86M -146M -57M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol REPL REPL REPL REPL REPL REPL
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-08 2023-11-07 2023-08-03 2023-05-18 2023-02-09 2022-11-03
acceptedDate 2024-02-08 08:09:58 2023-11-07 17:03:40 2023-08-03 08:11:14 2023-05-18 08:10:56 2023-02-09 08:17:33 2022-11-03 08:13:22
calendarYear 2024.000 2024.000 2024.000 2023.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
netIncome -51M -60M -50M -49M -40M -43M
depreciationAndAmortization 675 000 654 000 621 000 528 000 682 000 617 000
deferredIncomeTax -4M -957 000 -5M 0 0 0
stockBasedCompensation 8M 9M 9M 7M 7M 7M
changeInWorkingCapital -791 000 7M -3M 7M 5M 3M
accountsReceivables -414 000 -442 000 0 0 0 0
inventory 414 000 442 000 0 0 0 0
accountsPayables -476 000 -213 000 -816 000 2M -341 000 -197 000
otherWorkingCapital -315 000 8M -2M 5M 5M 3M
otherNonCashItems 273 000 256 000 -5M 2M -1M -404 000
netCashProvidedByOperatingActivities -47M -44M -49M -33M -29M -33M
investmentsInPropertyPlantAndEquipment -2M -2M -449 000 -251 000 -555 000 -396 000
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments -100M -112M -169M -150M -240M -133M
salesMaturitiesOfInvestments 156M 126M 177M 127M 116M 134M
otherInvestingActivites 0 0 0 0 0 0
netCashUsedForInvestingActivites 54M 13M 7M -23M -125M 36 000
debtRepayment -128 000 -113 000 -104 000 -103 000 -99 000 -86 000
commonStockIssued -2000.000 551 000 0 -248 000 150M 6M
commonStockRepurchased 0 0 0 93M 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 15M 0 1M -93M 121M 1M
netCashUsedProvidedByFinancingActivities 15M 438 000 1M -77 000 271M 7M
effectOfForexChangesOnCash -27 000 -16 000 13 000 -4M -8000.000 2M
netChangeInCash 22M -30M -40M -60M 118M -23M
cashAtEndOfPeriod 99M 78M 108M 148M 208M 91M
cashAtBeginningOfPeriod 78M 108M 148M 208M 91M 114M
operatingCashFlow -47M -44M -49M -33M -29M -33M
capitalExpenditure -2M -2M -449 000 -251 000 -555 000 -396 000
freeCashFlow -49M -45M -49M -33M -29M -34M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-02-08 13:00 ET
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
2024-01-16 08:59 ET
DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
2023-12-28 13:00 ET
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-05 12:00 ET
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
2023-11-08 14:10 ET
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
2023-11-07 13:00 ET
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
2023-11-03 23:30 ET
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunoth...
2023-09-19 20:01 ET
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-19 12:00 ET
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
2023-08-03 12:00 ET
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
2023-08-01 12:00 ET
Replimune to Present at Two Upcoming Investor Conferences
2023-07-20 12:00 ET
Replimune Announces Sander Slootweg will Depart from its Board of Directors
2023-06-06 14:00 ET
Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting
2023-06-05 12:00 ET
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
2023-06-03 18:15 ET
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
2023-06-01 20:01 ET
Replimune to Present at the Jefferies Global Healthcare Conference
2023-05-25 21:00 ET
Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
2023-05-18 12:00 ET
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
2023-05-09 12:00 ET
Replimune to Participate in the Piper Sandler Spring Biopharma Symposium
2023-03-08 13:00 ET
Replimune to Present at Two Upcoming Investor Conferences
2023-02-09 13:00 ET
Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update
2023-02-07 13:00 ET
Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
2023-01-04 13:05 ET
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-04 13:00 ET
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
2023-01-03 13:00 ET
Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-09 02:04 ET
Replimune Announces Pricing of Public Offering
2022-12-07 21:04 ET
Replimune Announces Proposed Public Offering
2022-12-07 12:00 ET
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
2022-12-07 11:30 ET
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
2022-11-23 13:00 ET
Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference
2022-11-22 13:00 ET
Replimune to Host Virtual Investor Event on December 7, 2022
2022-11-03 12:00 ET
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
2022-11-02 20:01 ET
Replimune to Present at Two Upcoming Investor Conferences
2022-08-04 12:00 ET
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
2022-08-01 20:01 ET
Replimune to Present at Two Upcoming Investor Conferences
2022-06-03 12:00 ET
Replimune Announces the Departure of Jason Rhodes from its Board of Directors
2022-06-02 12:00 ET
Replimune to Present at the Jefferies Healthcare Conference
2022-05-26 21:15 ET
Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
2022-05-19 12:00 ET
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update
2022-03-30 11:00 ET
Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
2022-03-21 12:00 ET
Replimune to Host Virtual Investor Event on March 30, 2022
2022-02-11 13:00 ET
Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2022-02-03 13:00 ET
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
2022-01-31 21:01 ET
Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors
2022-01-10 12:00 ET
Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones
2022-01-04 13:00 ET
Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-02 13:00 ET
Replimune Appoints Christy Oliger to its Board of Directors
2021-11-12 12:00 ET
Replimune Provides Updated Data from RP2 at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
2021-11-04 12:00 ET
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
2021-11-01 12:00 ET
Replimune to Present at Two Upcoming Investor Conferences
2021-10-01 12:01 ET
Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
2021-08-06 12:00 ET
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
2021-08-02 12:00 ET
Replimune to Present at Two Upcoming Investor Conferences
2021-07-07 12:00 ET
Replimune to Present at the William Blair Biotech Focus Conference 2021
2021-06-03 11:00 ET
Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1
2021-05-20 12:00 ET
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update
2021-05-10 12:00 ET
Replimune Appoints Tanya Lewis as Chief Development Operations Officer

SEC forms

Show financial reports only

SEC form 10
2024-02-08 00:00 ET
Replimune published news for 2023 q4
SEC form 8
2024-02-08 00:00 ET
Replimune reported for 2023 q4
SEC form 8
2024-02-08 00:00 ET
Replimune published news for 2023 q4
SEC form 10
2023-11-07 17:03 ET
Replimune reported for 2023 q3
SEC form 8
2023-11-07 08:15 ET
Replimune reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Replimune reported for 2023 q3
SEC form 6
2023-08-03 09:04 ET
Replimune published news for 2023 q2
SEC form 10
2023-08-03 08:11 ET
Replimune reported for 2023 q2
SEC form 6
2023-08-03 08:09 ET
Replimune reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Replimune reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Replimune reported for 2023 q2
SEC form 6
2023-07-26 20:00 ET
Replimune published news for 2023 q2
SEC form 6
2023-07-26 17:02 ET
Replimune published news for 2023 q2
SEC form 6
2023-07-20 08:56 ET
Replimune published news for 2023 q2
SEC form 6
2023-06-05 08:13 ET
Replimune published news for 2023 q1
SEC form 6
2023-06-05 08:11 ET
Replimune published news for 2023 q1
SEC form 6
2023-05-18 20:37 ET
Replimune published news for 2023 q1
SEC form 10
2023-05-18 08:10 ET
Replimune reported for 2023 q1
SEC form 6
2023-05-18 08:08 ET
Replimune reported for 2023 q1
SEC form 10
2023-05-18 00:00 ET
Replimune reported for 2023 q1
SEC form 8
2023-05-18 00:00 ET
Replimune reported for 2023 q1
SEC form 6
2023-02-27 08:49 ET
Replimune published news for 2022 q4
SEC form 10
2023-02-09 08:17 ET
Replimune reported for 2022 q4
SEC form 6
2023-02-09 08:15 ET
Replimune reported for 2022 q4
SEC form 8
2023-02-09 00:00 ET
Replimune reported for 2022 q4
SEC form 10
2023-02-09 00:00 ET
Replimune reported for 2022 q4
SEC form 6
2023-01-04 09:15 ET
Replimune published news for 2022 q4
SEC form 6
2022-12-12 17:00 ET
Replimune published news for 2022 q3
SEC form 6
2022-12-07 07:15 ET
Replimune published news for 2022 q3
SEC form 6
2022-12-05 20:00 ET
Replimune published news for 2022 q3
SEC form 10
2022-11-03 08:13 ET
Replimune reported for 2022 q3
SEC form 6
2022-11-03 08:11 ET
Replimune reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Replimune reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Replimune reported for 2022 q3
SEC form 6
2022-10-07 08:20 ET
Replimune published news for 2022 q3
SEC form 6
2022-09-08 16:10 ET
Replimune published news for 2022 q2
SEC form 10
2022-08-04 08:13 ET
Replimune reported for 2022 q2
SEC form 6
2022-08-04 08:10 ET
Replimune reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Replimune reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Replimune reported for 2022 q2
SEC form 6
2022-07-27 08:27 ET
Replimune published news for 2022 q2
SEC form 6
2022-06-23 16:25 ET
Replimune published news for 2022 q1
SEC form 6
2022-06-03 08:10 ET
Replimune published news for 2022 q1
SEC form 10
2022-05-19 08:11 ET
Replimune reported for 2022 q1
SEC form 6
2022-05-19 08:10 ET
Replimune reported for 2022 q1
SEC form 10
2022-05-19 00:00 ET
Replimune reported for 2022 q1
SEC form 8
2022-05-19 00:00 ET
Replimune reported for 2022 q1
SEC form 6
2022-03-30 07:28 ET
Replimune published news for 2021 q4
SEC form 10
2022-02-03 08:18 ET
Replimune published news for 2021 q4
SEC form 6
2022-02-03 08:16 ET
Replimune published news for 2021 q4
SEC form 8
2022-02-03 00:00 ET
Replimune published news for 2021 q4
SEC form 10
2022-02-03 00:00 ET
Replimune published news for 2021 q4
SEC form 6
2022-01-31 16:15 ET
Replimune published news for 2021 q4
SEC form 6
2022-01-10 08:29 ET
Replimune published news for 2021 q4
SEC form 6
2021-12-03 21:00 ET
Replimune published news for 2021 q3
SEC form 6
2021-12-02 09:15 ET
Replimune published news for 2021 q3
SEC form 10
2021-11-04 08:14 ET
Replimune published news for 2021 q3
SEC form 6
2021-11-04 08:13 ET
Replimune published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Replimune published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Replimune published news for 2021 q3
SEC form 6
2021-09-09 16:16 ET
Replimune published news for 2021 q2
SEC form 6
2021-08-25 16:15 ET
Replimune published news for 2021 q2
SEC form 10
2021-08-06 08:09 ET
Replimune published news for 2021 q2
SEC form 6
2021-08-06 08:00 ET
Replimune published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
Replimune published news for 2021 q2
SEC form 6
2021-07-22 16:00 ET
Replimune published news for 2021 q2
SEC form 6
2021-06-03 08:03 ET
Replimune published news for 2021 q1
SEC form 6
2021-05-20 08:06 ET
Replimune published news for 2021 q1
SEC form 10
2021-05-20 08:05 ET
Replimune published news for 2021 q1
SEC form 10
2021-05-20 00:00 ET
Replimune published news for 2021 q1
SEC form 6
2021-05-10 08:45 ET
Replimune published news for 2021 q1
SEC form 6
2021-05-05 21:00 ET
Replimune published news for 2021 q1
SEC form 6
2021-05-05 08:33 ET
Replimune published news for 2021 q1
SEC form 6
2021-04-21 08:54 ET
Replimune published news for 2021 q1
SEC form 6
2021-04-12 16:46 ET
Replimune published news for 2021 q1
SEC form 6
2021-02-04 08:26 ET
Replimune published news for 2020 q4
SEC form 10
2021-02-04 08:17 ET
Replimune published news for 2020 q4
SEC form 6
2021-01-11 07:48 ET
Replimune published news for 2020 q4
SEC form 6
2020-12-21 09:20 ET
Replimune published news for 2020 q3
SEC form 6
2020-11-05 08:19 ET
Replimune published news for 2020 q3
SEC form 10
2020-11-05 08:18 ET
Replimune published news for 2020 q3
SEC form 6
2020-11-03 16:06 ET
Replimune published news for 2020 q3
SEC form 6
2020-10-23 16:39 ET
Replimune published news for 2020 q3
SEC form 6
2020-10-21 21:32 ET
Replimune published news for 2020 q3
SEC form 6
2020-10-20 16:37 ET
Replimune published news for 2020 q3
SEC form 6
2020-10-19 17:13 ET
Replimune published news for 2020 q3
SEC form 6
2020-10-14 17:14 ET
Replimune published news for 2020 q3